AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

Medicover

Declaration of Voting Results & Voting Rights Announcements Feb 28, 2019

2943_rns_2019-02-28_c32729e8-50d6-4224-b551-facd94ce167c.pdf

Declaration of Voting Results & Voting Rights Announcements

Open in Viewer

Opens in native device viewer

Press Release Stockholm 28 February 2019

NUMBER OF SHARES AND VOTES IN MEDICOVER

The number of votes in Medicover AB (publ) ("Medicover") has changed as a result of conversions of in total 368,595 class A shares into class B shares carried out in February following requests from shareholders in accordance with the conversion clause in Medicover's articles of association.

Today, the last trading day of the month, there are in total 135,735,195 shares in Medicover, of which 78,836,201 are class A shares, together carrying 78,836,201 votes, 54,498,994 are class B shares, together carrying 5,449,899.40 votes and 2,400,000 are class C shares, together carrying 240,000 votes. The total number of votes in Medicover is 84,526,100.40.

For further information, please contact:

Hanna Bjellquist, Head of Investor Relations

+46 703 033 272 [email protected]

Medicover is required to publish the information contained in this press release pursuant to the Swedish Financial Instruments Trading Act. The information was provided for publication by the abovementioned contact person at 10.00 am CET on 28 February, 2019.

Medicover is a leading international healthcare and diagnostic services company and was founded in 1995. Medicover operates a large number of ambulatory clinics, hospitals, specialty-care facilities and laboratories and the largest markets are Poland and Germany. In 2017, Medicover had a revenue of €580 million and close to 15,900 employees. For more information, go to www.medicover.com

Talk to a Data Expert

Have a question? We'll get back to you promptly.